AEGIS BIO
AEGIS BIO is a preclinical-stage biotechnology company developing small molecules designed to be used alongside DNA-damaging cancer treatments like cisplatin to reduce severe toxicities while enhancing antitumor activity. Its lead candidate, TIX047, targets pediatric, head and neck, and testicular cancers, with in vivo proof of concept already demonstrated.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Severe side effects remain a major limitation of cancer treatment, compromising efficacy, restricting clinical use, and preventing regulatory approval. Cisplatin, used in 10-20% of all tumors, causes ototoxicity in 75% of children and 25-50% of adults, nephrotoxicity in 90% of patients, and peripheral neurotoxicity in 50% of patients, often forcing dose reductions that compromise treatment outcomes.
Solution
AEGIS BIO develops small molecules designed to be used alongside DNA-damaging cancer treatments like cisplatin, with the goal of reducing toxicity while enhancing antitumor activity. The company's approach aims to shield healthy organs from severe and potentially irreversible toxicities, allowing patients to maintain full treatment intensity rather than requiring dose reductions. Preclinical evidence includes in vivo protection demonstrated for the lead candidate, with protective activity observed in vivo and additional validation underway. Initially focused on cisplatin, the approach has the potential to extend to a broader range of DNA-damaging cancer treatments.
Target Audience
Primary customers are oncology drug developers and pharmaceutical partners seeking supportive care therapies that reduce chemotherapy toxicity, with particular relevance for pediatric oncology and cisplatin-treated patient populations.
Features
- Two-candidate pipeline: TIX047 (lead candidate) designed to reduce multiple cisplatin-associated toxicities while enhancing antitumor activity, and TIX022 (preclinical candidate) supporting pipeline breadth
- TIX047 targets pediatric cancers, head and neck cancers, and testicular cancers
- In vivo proof of concept demonstrated, with protective activity observed in vivo
- Small-molecule approach designed for combination use with established chemotherapy regimens
- Pipeline progressing through lead identification, candidate selection, preclinical efficacy, PK/PD and formulation, and IND-enabling stages